Effects of D1 and D2 dopamine receptor agents on ethanol consumption in the high-alcohol-drinking (HAD) line of rats

doi:10.1016/0741-8329(93)90037-O

Alcohol

Volume 10, Issue 3, May–June 1993, Pages 207-212

https://doi.org/10.1016/0741-8329(93)90037-O Get rights and content

Abstract

Dopamine receptor agonists and antagonists were tested for effects on alcohol drinking in female HAD rats (n = 10) given limited access (4 h/day) to a 10% (v/v) ethanol solution. Food and water were available ad libitum. Subcutaneous drug injections were given 30–60 min before the ethanol access periods. The D₂ agonist quinpirole (0.04–2.0 mg/kg) caused a dose-dependent decrease in alcohol drinking throughout the 4-h period. Spiperone, a D₂ antagonist, had no effect during the initial part of the session, but by the fourth hour, the 10 μg/kg dose tended to increase alcohol intake and the 30 μg/kg dose reduced intake. The D₁ antagonist SCH-23390 (3–30 μg/kg) dose-dependently decreased ethanol drinking during the first hour of access. The D₁ agonist SKF-38393 (2–6 mg/kg) also decreased alcohol intake, but it was less effective than SCH-23390. The findings implicate both D₁ and D₂ receptors in the reinforcing effects of alcohol drinking by the HAD line of rats.

References (36)

D.R. Britton et al.
Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration
Pharmacol. Biochem. Behav.
(1991)
Z.W. Brown et al.
Lack of effect of dopamine receptor blockade on voluntary ethanol consumption in rats
Behav. Neural Biol.
(1982)
G.L. Gessa et al.
Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area
Brain Res.
(1985)
M.A. Gongwer et al.
Regional brain contents of serotonin, dopamine and their metabolites in the selectively bred high- and low-alcohol drinking lines of rats
Alcohol
(1989)
E.C. Krimmer et al.
HAD and LAD rats respond differently to stimulating effect but not discriminative effects of ethanol
Alcohol
(1992)
E.D. Levin et al.
Interactive effects of D₁ and D₂ agonists with scopolamine on radial-arm maze performance
Pharmacol. Biochem. Behav.
(1991)
L. Lumeng et al.
New strains of rats with alcohol preference and nonpreference
W.J. McBride et al.
Serotonin, dopamine and GABA involvement in alcohol drinking of selectively bred rats
Alcohol
(1990)
J.T. McDevitt et al.
Differential effects of dopamine agonists in mature and immature rats
Eur. J. Pharmacol.
(1981)
J.M. Murphy et al.
Effects of scheduled access on ethanol intake by the alcohol-preferring (P) line of rats
Alcohol
(1986)

J.M. Murphy et al.

Contents of monoamines in forebrain regions of alcohol-preferring (P) and -nonpreferring (NP) lines of rats

Pharmacol. Biochem. Behav.

(1987)

S. Nakajima

Subtypes of dopamine receptors involved in the mechanism of reinforcement

Neurosci. Biobehav. Rev.

(1989)

A.O. Pfeffer et al.

Effect of pimozide on home cage ethanol drinking in the rat: Dependence on drinking session length

Drug Alcohol Depend.

(1986)

A.O. Pfeffer et al.

Haloperidol and apomorphine effects on ethanol reinforcement in free feeding rats

Pharmacol. Biochem. Behav.

(1988)

M.B. Waller et al.

Effect of low dose ethanol on spontaneous motor activity in alcohol-preferring and -nonpreferring lines of rats

Pharmacol. Biochem. Behav.

(1986)

K. Yoshimoto et al.

Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens

Alcohol

(1992)

V. Borg

Bromocriptine in the prevention of alcohol abuse

Acta Psychiatr. Scand.

(1983)

C.R. Cloninger

Neurogenetic adaptive mechanisms in alcoholism

Science

(1987)

Cited by (139)

Reciprocal midbrain-extended amygdala circuit activity in preclinical models of alcohol use and misuse
2022, Neuropharmacology
Alcohol dependence is characterized by a shift in motivation to consume alcohol from positive reinforcement (i.e., increased likelihood of future alcohol drinking based on its rewarding effects) to negative reinforcement (i.e., increased likelihood of future alcohol drinking based on alcohol-induced reductions in negative affective symptoms, including but not limited to those experienced during alcohol withdrawal). The neural adaptations that occur during this transition are not entirely understood. Mesolimbic reinforcement circuitry (i.e., ventral tegmental area [VTA] neurons) is activated during early stages of alcohol use, and may be involved in the recruitment of brain stress circuitry (i.e., extended amygdala) during the transition to alcohol dependence, after chronic periods of high-dose alcohol exposure. Here, we review the literature regarding the role of canonical brain reinforcement (VTA) and brain stress (extended amygdala) systems, and the connections between them, in acute, sub-chronic, and chronic alcohol response. Particular emphasis is placed on preclinical models of alcohol use.
This article is part of the special Issue on ‘Neurocircuitry Modulating Drug and Alcohol Abuse'.
Rat animal models for screening medications to treat alcohol use disorders
2017, Neuropharmacology
Citation Excerpt :
Given the multiple genes, each contributing a relatively small effect-size, mediating the genetic risk for developing AUD; it is not surprising that there are different drinking, including relapse, profiles among the selected lines (Table 2). Examples of neurotransmitters and neuromodulators modulating relapse to ethanol intake include the adrenergic (alpha: Froehlich et al., 2013a), cannabinoid (Dyr et al., 2008; Gessa et al., 2005; Hansson et al., 2007), cholinergic (Bell et al., 2009a; Sotomayor-Zarate et al., 2013), dopaminergic (Dyr et al., 1993; Thanos et al., 2005), GABAergic (GABRA: Agabio et al., 1998; GABRA-BDZ complex: June et al., 1998b; McKay et al., 2004; GABRB: Maccioni et al., 2012; Quintanilla et al., 2008), glutamatergic (Bilbeny et al., 2005; Cowen et al., 2005b; Sari et al., 2013a), histaminergic (Lintunen et al., 2001), opioid (pan-opioid: Hyytiä and Sinclair, 1993; June et al., 1998d; MOR: Honkanen et al., 1996; Krishnan-Sarin et al., 1998; DOR: Hyytiä and Kiianmaa, 2001; Sigma: Sabino et al., 2009a), and serotonergic (Long et al., 1996; Overstreet et al., 1997; Panocka et al., 1995b; West et al., 2011) systems (Table 6). Unfortunately, only the P, HAD1, HAD2, and sP rat lines have been consistently used to assess compound efficacy in disrupting relapse-like behavior.
The purpose of this review is to present animal research models that can be used to screen and/or repurpose medications for the treatment of alcohol abuse and dependence. The focus will be on rats and in particular selectively bred rats. Brief introductions discuss various aspects of the clinical picture, which provide characteristics of individuals with alcohol use disorders (AUDs) to model in animals. Following this, multiple selectively bred rat lines will be described and evaluated in the context of animal models used to screen medications to treat AUDs. Next, common behavioral tests for drug efficacy will be discussed particularly as they relate to stages in the addiction cycle. Tables highlighting studies that have tested the effects of compounds using the respective techniques are included. Wherever possible the Tables are organized chronologically in ascending order to describe changes in the focus of research on AUDs over time. In general, high ethanol-consuming selectively bred rats have been used to test a wide range of compounds. Older studies usually followed neurobiological findings in the selected lines that supported an association with a propensity for high ethanol intake. Most of these tests evaluated the compound's effects on the maintenance of ethanol drinking. Very few compounds have been tested during ethanol-seeking and/or relapse and fewer still have assessed their effects during the acquisition of AUDs. Overall, while a substantial number of neurotransmitter and neuromodulatory system targets have been assessed; the roles of sex- and age-of-animal, as well as the acquisition of AUDs, ethanol-seeking and relapse continue to be factors and behaviors needing further study.
This article is part of the Special Issue entitled “Alcoholism”.
Distinct Synaptic Strengthening of the Striatal Direct and Indirect Pathways Drives Alcohol Consumption
2017, Biological Psychiatry
Repeated exposure to addictive drugs or alcohol triggers glutamatergic and gamma-aminobutyric acidergic (GABAergic) plasticity in many neuronal populations. The dorsomedial striatum (DMS), a brain region critically involved in addiction, contains medium spiny neurons (MSNs) expressing dopamine D₁ or D₂ receptors, which form direct and indirect pathways, respectively. It is unclear how alcohol-evoked plasticity in the DMS contributes to alcohol consumption in a cell type–specific manner.
Mice were trained to consume alcohol using an intermittent-access two-bottle-choice drinking procedure. Slice electrophysiology was used to measure glutamatergic and GABAergic strength in DMS D₁- and D₂-MSNs of alcohol-drinking mice and control mice. In vivo chemogenetic and pharmacologic approaches were employed to manipulate MSN activity, and their consequences on alcohol consumption were measured.
Repeated cycles of alcohol consumption and withdrawal in mice strengthened glutamatergic transmission in D₁-MSNs and GABAergic transmission in D₂-MSNs. In vivo chemogenetic excitation of D₁-MSNs, mimicking glutamatergic strengthening, promoted alcohol consumption; the same effect was induced by D₂-MSN inhibition, mimicking GABAergic strengthening. Importantly, suppression of GABAergic transmission via D₂ receptor–glycogen synthase kinase–3β signaling dramatically reduced excessive alcohol consumption, as did selective inhibition of D₁-MSNs or excitation of D₂-MSNs.
Our results suggest that repeated cycles of excessive alcohol intake and withdrawal potentiate glutamatergic strength exclusively in D₁-MSNs and GABAergic strength specifically in D₂-MSNs of the DMS, which concurrently contribute to alcohol consumption. These results provide insight into the synaptic and cell type–specific mechanisms underlying alcohol addiction and identify targets for the development of new therapeutic approaches to alcohol abuse.
Alcohol consumption in adolescent rats treated with reserpine and fluoxetine
2017, Suma Psicologica
Si bien se ha estudiado el vínculo entre los trastornos de estado de ánimo y el consumo de alcohol, tanto en humanos como en animales, todavía no es del todo claro cómo se da esta relación, y menos aún durante la adolescencia. La administración de reserpina, un depletor de monoaminas, es un modelo ampliamente utilizado en roedores adultos para inducir comportamientos asociados a depresión, pero se desconoce su utilidad en otras etapas del desarrollo. En este trabajo validamos este modelo en ratas adolescentes y posteriormente estudiamos el consumo de alcohol en estos animales, así como su modulación por antidepresivos. En el experimento 1 se administró reserpina (0.0 o 1.0 mg/kg, durante 4 días, IP) a ratas Wistar machos de 30 días. El consumo de alcohol fue evaluado luego de observar comportamientos asociados a depresión e indagar indicadores neuroendocrinos de esta patología. En el experimento 2 los animales recibieron reserpina, seguida por el antidepresivo fluoxetina (0.0 o 10.0 mg/kg, durante 4 días, IG), y luego se evaluó el consumo de alcohol. Los resultados mostraron que la reserpina aumentó significativamente los comportamientos asociados a depresión y alteró los niveles de dopamina en la corteza insular y de hormonas tiroideas en sangre. En la prueba de consumo de alcohol los animales deprimidos, pero no los controles, mostraron un incremento en el consumo a través de los días. El segundo experimento replicó parcialmente este perfil, y no se observó un efecto significativo del antidepresivo en el consumo de alcohol. Los resultados indican que la reserpina es útil para modelar en ratas adolescentes comportamientos asociados a depresión. Se encontró una relación entre este estado y el consumo de alcohol, que no se pudo revertir con antidepresivos.
The relationship between mood disorders and alcohol consumption has been studied in humans and animals, although it is still not fully clear how this relationship unfolds, much less during adolescence. The administration of reserpine — a monoamine depletor — is an approach traditionally used in adult rodents to induce depression-associated behaviours, but its usefulness in other developmental stages is still unknown. In this study, this model was evaluated in adolescent rats in order to study alcohol consumption, as well as its modulation by antidepressants in these animals. In Experiment 1, 30 day-old male Wistar rats were treated with reserpine (0.0 or 1.0 mg/kg, for 4 days, IP). Alcohol consumption was tested after observing depression-associated behaviours and assessing neuroendocrine indicators of this pathology. In Experiment 2, the rats were administered reserpine followed by an antidepressant (fluoxetine, 0.0 or 10.0 mg/kg, for 4 days, IG). Alcohol consumption was then tested. The results showed that reserpine significantly increased depression-associated behaviours and altered insular dopamine and thyroid hormone levels. Alcohol consumption tests showed that reserpine-treated animals — but not control animals — increased their consumption throughout the days. The second experiment partially replicated this profile, and no significant effect of antidepressants was observed in alcohol consumption. The results show that reserpine is instrumental in modelling depression-associated behaviours in adolescent rats. A relationship was found between this condition and alcohol intake, which could not be reversed by antidepressants.
Rodent models and mechanisms of voluntary binge-like ethanol consumption: Examples, opportunities, and strategies for preclinical research
2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Citation Excerpt :
These findings demonstrate that ethanol exposure does not need to be contingent with consumption to elevate extracellular DA, suggesting this observation is simply a reflection of ethanol's pharmacological effects. Although GBR 12909 itself has not been extensively studied, activation of DA receptors via agonists has been shown to reduce ethanol intake across a variety of rodent genotypes and paradigms (Cohen et al., 1999; Dyr et al., 1993; Ng and George, 1994; Silvestre et al., 1996). However, sucrose or saccharin solution intake was also observed to be reduced in a number of these studies (Cohen et al., 1999; Dyr et al., 1993; Kamdar et al., 2007).
Binge ethanol consumption has widespread negative consequences for global public health. Rodent models offer exceptional power to explore the neurobiology underlying and affected by binge-like drinking as well as target potential prevention, intervention, and treatment strategies. An important characteristic of these models is their ability to consistently produce pharmacologically-relevant blood ethanol concentration. This review examines the current available rodent models of voluntary, pre-dependent binge-like ethanol consumption and their utility in various research strategies. Studies have demonstrated that a diverse array of neurotransmitters regulate binge-like drinking, resembling some findings from other drinking models. Furthermore, repeated binge-like drinking recruits neuroadaptive mechanisms in mesolimbocortical reward circuitry. New opportunities that these models offer in the current context of mechanistic research are also discussed.
Lack of effect of nucleus accumbens dopamine D1 receptor blockade on consumption during the first two days of operant self-administration of sweetened ethanol in adult Long-Evans rats
2015, Alcohol
The mechanisms underlying ethanol self-administration are not fully understood; however, it is clear that ethanol self-administration stimulates nucleus accumbens dopamine release in well-trained animals. During operant sweetened ethanol self-administration behavior, an adaptation in the nucleus accumbens dopamine system occurs between the first and second exposure, paralleling a dramatic increase in sweetened ethanol intake, which suggests a single exposure to sweetened ethanol may be sufficient to learn the association between sweetened ethanol cues and its reinforcing properties. In the present experiment, we test the effects of blockade of nucleus accumbens dopamine D1 receptors on operant sweetened ethanol self-administration behavior during the first 2 days of exposure. Adult male Long-Evans rats were first trained to self-administer 10% sucrose (10S) across 6 days in an appetitive and consummatory operant model (appetitive interval: 10-min pre-drinking wait period and a lever response requirement of 4; consummatory interval: 20-min access to the drinking solution). After training on 10S, the drinking solution was switched to 10% sucrose plus 10% ethanol (10S10E); control rats continued drinking 10S throughout the experiment. Bilateral nucleus accumbens microinjections of the dopamine D1 antagonist, SCH-23390 (0, 1.0, or 3.0 μg/side), immediately preceded the first two sessions of drinking 10S10E. Results show that blocking nucleus accumbens dopamine D1 receptors has little or no influence on consumption during the first 2 days of exposure to the sweetened ethanol solution or maintenance of sucrose-only drinking. Furthermore, the high dose of SCH-23390, 3.0 μg/side, reduced open-field locomotor activity. In conclusion, we found no evidence to suggest that nucleus accumbens D1 receptor activation is involved in consumption of a sweetened ethanol solution during the first 2 days of exposure or maintenance of sucrose drinking, but rather D1 receptors seem necessary for general locomotor activity that contributes to initiation of appetitive behavior.

View all citing articles on Scopus

¹: Permanent address: Department of Pharmacology and Physiology of the Nervous System, Institute of Psychiatry and Neurology, Al. Sobieskiego 1-9, Warsaw 02-957, Poland.

View full text

ArticleEffects of D1 and D2 dopamine receptor agents on ethanol consumption in the high-alcohol-drinking (HAD) line of rats

Abstract

Pharmacol. Biochem. Behav.

Behav. Neural Biol.

Brain Res.

Alcohol

Alcohol

Pharmacol. Biochem. Behav.

Alcohol

Eur. J. Pharmacol.

Alcohol

Pharmacol. Biochem. Behav.

Neurosci. Biobehav. Rev.

Drug Alcohol Depend.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Alcohol

Bromocriptine in the prevention of alcohol abuse

Acta Psychiatr. Scand.

Neurogenetic adaptive mechanisms in alcoholism

Science

Article
Effects of D₁ and D₂ dopamine receptor agents on ethanol consumption in the high-alcohol-drinking (HAD) line of rats